<?xml version='1.0' encoding='utf-8'?>
<document id="30538075"><sentence text="The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics."><entity charOffset="17-28" id="DDI-PubMed.30538075.s1.e0" text="telmisartan" /><entity charOffset="32-41" id="DDI-PubMed.30538075.s1.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30538075.s1.e0" e2="DDI-PubMed.30538075.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s1.e0" e2="DDI-PubMed.30538075.s1.e1" /></sentence><sentence text="Metformin is the most widely used drug among type 2 diabetes mellitus patients"><entity charOffset="0-9" id="DDI-PubMed.30538075.s2.e0" text="Metformin" /></sentence><sentence text=" However, drug interaction on metformin will influence its glucose-lowering effect or increase its side effect of lactic acidosis"><entity charOffset="30-39" id="DDI-PubMed.30538075.s3.e0" text="metformin" /><entity charOffset="59-66" id="DDI-PubMed.30538075.s3.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.30538075.s3.e0" e2="DDI-PubMed.30538075.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s3.e0" e2="DDI-PubMed.30538075.s3.e1" /></sentence><sentence text=" In this study, a randomized, two-stage, crossover study was conducted to unveil the potential drug interaction between metformin and the anti-hypertension drug, telmisartan"><entity charOffset="120-129" id="DDI-PubMed.30538075.s4.e0" text="metformin" /><entity charOffset="162-173" id="DDI-PubMed.30538075.s4.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.30538075.s4.e0" e2="DDI-PubMed.30538075.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s4.e0" e2="DDI-PubMed.30538075.s4.e1" /></sentence><sentence text=" Totally, 16 healthy Chinese male volunteers were enrolled" /><sentence text=" Blood samples from various time-points after drug adminstration were analyzed for metformin quantification"><entity charOffset="83-92" id="DDI-PubMed.30538075.s6.e0" text="metformin" /></sentence><sentence text=" Oral glucose tolerance test (OGTT) was conducted 2 h after metformin administration"><entity charOffset="6-13" id="DDI-PubMed.30538075.s7.e0" text="glucose" /><entity charOffset="60-69" id="DDI-PubMed.30538075.s7.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30538075.s7.e0" e2="DDI-PubMed.30538075.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s7.e0" e2="DDI-PubMed.30538075.s7.e1" /></sentence><sentence text=" The AUC0-12 and Cmax of metformin in subjects co-administrated with telmisartan were significantly lower than with placebo"><entity charOffset="25-34" id="DDI-PubMed.30538075.s8.e0" text="metformin" /><entity charOffset="69-80" id="DDI-PubMed.30538075.s8.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.30538075.s8.e0" e2="DDI-PubMed.30538075.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s8.e0" e2="DDI-PubMed.30538075.s8.e1" /></sentence><sentence text=" The geometric mean ratios (value of metformin plus telmisartan phase/value of metformin plus placebo phase) for Cmax and AUC0-12 is 0"><entity charOffset="37-46" id="DDI-PubMed.30538075.s9.e0" text="metformin" /><entity charOffset="52-63" id="DDI-PubMed.30538075.s9.e1" text="telmisartan" /><entity charOffset="79-88" id="DDI-PubMed.30538075.s9.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30538075.s9.e0" e2="DDI-PubMed.30538075.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s9.e0" e2="DDI-PubMed.30538075.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30538075.s9.e0" e2="DDI-PubMed.30538075.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30538075.s9.e1" e2="DDI-PubMed.30538075.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30538075.s9.e1" e2="DDI-PubMed.30538075.s9.e2" /></sentence><sentence text="7972 (90%CI: 0" /><sentence text="7202-0" /><sentence text="8824) and 0" /><sentence text="8336 (90%CI: 0" /><sentence text="7696-0" /><sentence text="9028), respectively" /><sentence text=" Moreover, telmisartan co-administration significantly increased the plasma concentrations of both glucose and insulin at 0"><entity charOffset="11-22" id="DDI-PubMed.30538075.s16.e0" text="telmisartan" /><entity charOffset="99-106" id="DDI-PubMed.30538075.s16.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.30538075.s16.e0" e2="DDI-PubMed.30538075.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s16.e0" e2="DDI-PubMed.30538075.s16.e1" /></sentence><sentence text="5 h since OGTT (7" /><sentence text="64 ± 1" /><sentence text="86 mmol/l·min vs 6" /><sentence text="77 ± 0" /><sentence text="83 mmol/l·min, P = 0" /><sentence text="040; 72" /><sentence text="91 ± 31" /><sentence text="98 μIU/ml·min vs 60" /><sentence text="20 ± 24" /><sentence text="20 μIU/ml·min, P = 0" /><sentence text="037), though the AUC of glucose and insulin after OGTT showed no significant difference"><entity charOffset="24-31" id="DDI-PubMed.30538075.s27.e0" text="glucose" /></sentence><sentence text=" These findings suggested that telmisartan had a significant influence on the Pharmacokinetics of metformin in healthy groups, though the influence on glucose-lowering effect was moderate"><entity charOffset="31-42" id="DDI-PubMed.30538075.s28.e0" text="telmisartan" /><entity charOffset="98-107" id="DDI-PubMed.30538075.s28.e1" text="metformin" /><entity charOffset="151-158" id="DDI-PubMed.30538075.s28.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.30538075.s28.e0" e2="DDI-PubMed.30538075.s28.e0" /><pair ddi="false" e1="DDI-PubMed.30538075.s28.e0" e2="DDI-PubMed.30538075.s28.e1" /><pair ddi="false" e1="DDI-PubMed.30538075.s28.e0" e2="DDI-PubMed.30538075.s28.e2" /><pair ddi="false" e1="DDI-PubMed.30538075.s28.e1" e2="DDI-PubMed.30538075.s28.e1" /><pair ddi="false" e1="DDI-PubMed.30538075.s28.e1" e2="DDI-PubMed.30538075.s28.e2" /></sentence><sentence text="" /></document>